Inhibition of azoxymethane-induced colorectal cancer by CP-31398, a TP53 modulator, alone or in combination with low doses of celecoxib in male F344 rats

Cancer Research

Volumn 69, Issue 20, 2009, Pages 8175-8182

  Rao, Chinthalapally V ^a   Steele, Vernon E ^b   Swamy, Malisetty V ^a   Patlolla, Jagan M R ^a   Guruswamy, Suresh ^a   Kopelovich, Levy ^b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; AZOXYMETHANE; CARCINOGEN; CELECOXIB; PROTEIN P21; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INCIDENCE; CANCER MODEL; CELL PROLIFERATION; CHEMOPROPHYLAXIS; COLON ADENOCARCINOMA; COLORECTAL CANCER; CONTROLLED STUDY; DIET; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG INHIBITION; FEEDING; FISCHER 344 RAT; LOW DRUG DOSE; MALE; NONHUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TUMOR CELL;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; AZOXYMETHANE; BLOTTING, WESTERN; CARCINOGENS; CELL PROLIFERATION; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; DRUG THERAPY, COMBINATION; IMMUNOENZYME TECHNIQUES; IN SITU NICK-END LABELING; MALE; MAXIMUM TOLERATED DOSE; MEMBRANE PROTEINS; PYRAZOLES; PYRIMIDINES; RATS; RATS, INBRED F344; SULFONAMIDES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 70350234715     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-1377     Document Type: Article

References (50)

1. Potter JD. Risk factors for colon neoplasia - epidemiology and biology. Eur J Cancer 1995;31:1033-1038
2. Slattery ML, Curtin K, Ma K, et al. Diet, activity, and lifestyle associations with p53 mutations in colon tumors. Cancer Epidemiol Biomarkers Prev 2002;11:541-548 (Pubitemid 34615161)
3. Heavey PM, McKenna D, Rowland IR. Colorectal cancer and the relationship between genes and the environment. Nutr Cancer 2004;48:124-141 (Pubitemid 39045774)
4. Kinzler KW, Vogelstein B. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 1997;386:761-763
5. Vogelstein BFE, Hamilton SR, Kern SE, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-532
6. Bullock AN, Fersht AR. Rescuing the function of mutant p53. Nat Rev Cancer 2001;1:68-76.
7. Vousden K. p53 death star. Cell 2000;103:691-694
8. Kopelovich L, DeLeo AB. Elevated levels of p53 antigen in cultured skin fibroblasts from patients with hereditary adenocarcinoma of the colon and rectum and its relevance to oncogenic mechanisms. J Natl Cancer Inst 1986;77:1241-1246 (Pubitemid 17005100)
9. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004;10:789-799 (Pubitemid 39070849)
10. Kastan MB. Wild-type p53: tumors can't stand it. Cell 2007;128:837-840
11. Bullock AN, Henckel J, Fersht AR. Quantitative analysis of residual folding and DNAbinding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene 2000;19:1245-1256 (Pubitemid 30160617)
12. Ventura A, Kirsch DG, McLaughlin ME, et al. Restoration of p53 function leads to tumor regression in vivo . Nature 2007;445:661-665 (Pubitemid 46232887)
13. Abarzua P, LoSardo JE, Gubler ML, et al. Restoration of the transcription activation function to mutant p53 in human cancer cells. Oncogene 1996;13:2477-2482 (Pubitemid 27026032)
14. Foster BA, Coffey HA, Morin MJ, Rastinejad F. Pharmacological rescue of mutant p53 conformation and function. Science 1999;286:2507-2510 (Pubitemid 30026339)
15. Wang W, Takimoto R, Ratinejad F, El-Diery W. Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol Cell Biol 2003;23:2171-2181 (Pubitemid 36278825)
16. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small molecules antagonists of MDM2. Science 2004;303:844-848
17. Demma MJ, Wong S, Maxwell E, Dasmahapatra B. CP-31398 restores DNA-binding activity to mutant p53 in vitro but does not affect p53 homologs p63 and p73. J Biol Chem 2004;44:45887-45896 (Pubitemid 39491581)
18. Wang W, Kim S-H, El-Deiry WS. Small molecule modulators of p53 family signaling and anti-tumor effects in 53-deficient human colon tumor xenografts. Proc Natl Acad Sci U S A 2006;103:11003-11008 (Pubitemid 44148408)
19. Tang X, Zhu Y, Han L, et al. CP-31398 restores mutant p53 tumor suppressor function and inhibits UAB-induced skin carcinogenesis in mice. J Clin Invest 2007;117:3753-3764 (Pubitemid 350224086)
20. min/+ mice. Cancer Res 2008;68:7670-7675
21. Marnett LJ, DuBois RN. COX-2: a target for colon cancer prevention. Annu Rev Pharmacol Toxicol 2002; 42:55-80. (Pubitemid 34160519)
22. Reddy BS, Rao CV. Novel approaches for colon cancer prevention by cyclooxygenase-2 inhibitors. J Environ Pathol Toxicol Oncol 2002;21:155-164 (Pubitemid 34655036)
23. Reddy BS, Hirose Y, Lubet R, et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 2000;60:293-297 (Pubitemid 30070754)
24. Kawamori T, Rao CV, Seibert K, et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase- 2 inhibitor, against colon carcinogenesis. Cancer Res 1998;58:409-412 (Pubitemid 28087398)
25. Swamy MV, Herzog CR, Rao CV. Celecoxib inhibition of COX-2 in colon cancer cell lines increases the nuclear localization of functionally active p53. Cancer Res 2000; 63:5239-5242
26. Rao CV, Wang CQ, Simi B, et al. Chemoprevention of colon cancer by a glutathione conjugate of 1,4-phenylenebis( methylene) selenocyanate, a novel organoselenium compound with low toxicity. Cancer Res 2001;61: 3647-3652 (Pubitemid 32694975)
27. Bird RP. Observation and quantification of aberrant crypts in themurine colon treatedwith a colon carcinogen: preliminary findings. Cancer Lett 1987;37:147-151
28. Rao CV, Indranie C, Simi B, et al Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase- 2 inhibitor. Cancer Res 2002;62:165-170 (Pubitemid 34074001)
29. Janakiram NB, Steele VE, Rao CV. Estrogen receptor-β as a potential target for colon cancer prevention: chemoprevention of azoxymethane-induced colon carcinogenesis by raloxifene in F344 rats. Cancer Prev Res 2009;2:52-59
30. Rao CV, Reddy BS, Steele VE, et al. Nitric oxidereleasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets. Mol Cancer Ther 2006;5: 1530-1538
31. Reddy BS, Wang CX, Kong AN, et al. Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F344 rats. Cancer Res 2006;66:4542-4546
32. Bykov VJN, Issaeva N, Shilov A, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 2002;8:282-288 (Pubitemid 34250107)
33. Luu Y, Bush J, Cheung K-J, Jr., Li G. The p53 stabilizing compound CP-31398 induces apoptosis by activating the intrinsic bax/mitochondrial/ caspase-9 pathway. Exp Cell Res 2002;276:214-222 (Pubitemid 34969315)
34. Rodrigues NR, Rowan A, Smith MEF, et al. p53 mutations in colorectal cancer. Proc Natl Acad Sci U S A 1990;87:7555-7559
35. Takimoto R, Wang W, Dicker DT, Rastinejad F, Lyssikatos J, El-Diery WS. The mutant p53-conformation modifying drug, CP-31398 can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biol Ther 2002;1:47-55.
36. Xue W, Zender L, Miething C, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007;445:656-660 (Pubitemid 46232886)
37. Bernal F, Tyler AF, Korsmeyer SJ, Walensky LD, Verdine GL. Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide. J Am Chem Soc 2007; 129:2456-2457 (Pubitemid 46364050)
38. Nahi H, Lehmann S, Mollgard L, et al. Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion. Br J Haematol 2004;127:285-291 (Pubitemid 39468941)
39. Reddy BS, Rao CV. Chemoprophylaxis of colon cancer. Curr Gastroenterol Rep 2005;7:389-395
40. Bertagnolli MM, Eagle CJ, Zaubar AG, et al. Five-year efficacy and safety analysis of the adenoma prevention with celecoxib trial. Cancer Prev Res 2009;2:310-321
41. Rao CV, Reddy BS. NSAIDs and chemoprevention. Curr Cancer Drug Targets 2004;4:29-42.
42. Marnett LJ. The COXIB experience: a look in the rear-view mirror. Annu Rev Pharmacol Toxicol 2009;49:265-290
43. DuBiois RN. New, long-term insights from the adenoma prevention with celecoxib trial on a promising but troubled class of drugs. Cancer Prev Res 2009;2:285-287
44. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-1102 (Pubitemid 40365350)
45. Rao CV, Rivenson A, Simi B, et al. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res 1995;55:1464-1472
46. Rao CV, Rivenson A, Simi B, Reddy BS. Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res 1995;55:259-266
47. Rao CV, Rivenson A, Katiwalla M, et al. Chemopreventive effect of oltipraz during different stages of experimental colon carcinogenesis induced by azoxymethane in male F344 rats. Cancer Res 1993;53: 2502-2506 (Pubitemid 23168013)
48. Rao CV, Tokumo K, Rigotty J, et al. Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, α- difluoromethylornithine, 16α-fluoro-5-androsten-17-one, and ellagic acid individually and in combination. Cancer Res 1991;51:4528-4534
49. Min mice. Cancer Res 2006;66:7370-7377
50. Moos PJ, Edes K, Fitzpatrick FA. Inactivation of wild-type p53 tumor suppressor by electrophilic prostaglandins. Proc Natl Acad Sci U S A 2000;97:9215-9220 (Pubitemid 30626700)